CA-CONVIVA
24.8.2022 16:03:10 CEST | Business Wire | Press release
Conviva , the leading global streaming analytics platform, has been recognized by the Association for Computing Machinery’s Special Interest Group on Data Communications (ACM SIGCOMM) with two prestigious innovation awards: the ACM SIGCOMM Test of Time Award and the SIGCOMM Networking Systems Award. Both awards honor the vision and impact of Conviva’s commitment to data and analytics technology innovation that began with the founding team of Hui Zhang, Aditya Ganjam, Jibin Zhan (Conviva) and Ion Stoica (Conviva, Databricks) defining standards that pushed the industry forward. This team’s work has continued to be foundational to enabling and continuously improving the quality and overall end-user experience that is industry standard in streaming media today. This same core technology has also proven applicable to virtually any industry where technology and business leaders have a business imperative to make the vast amount of their data available to their organizations in real time, and actionable across every aspect of their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220824005274/en/
2022 SIGCOMM Test of Time Award
The 2022 ACM SIGCOMM Test of Time Award honors Conviva’s founders for their 2011 paper detailing the direct connection between video quality and user engagement. The annual award recognizes papers published 10 to 12 years in the past that are deemed to offer data, perspective and predictions that still have significance today.
“What we didn’t predict was who would be the winners and losers of the streaming wars,” said Hui Zhang, Conviva Cofounder, Chief Scientist and Chairman of the Board. “What we did know ten years ago, and still holds true today, is that measuring quality and engagement in streaming is core to market growth and who comes out on top. Having this real-time information at their fingertips is mission-critical for publishers and brands to inform any actions to optimize their services and maximize their investment.”
The breakthrough technology that underscored the Test of Time award was documented in a paper, “Understanding the Impact of Video Quality on User Engagement” that was first presented at the 2011 ACM SIGCOMM conference. Its authors were Conviva founders Hui Zhang, Ion Stoica, Aditya Ganjam and Jibin Zhan, along with teammates Florin Dobrian, Asad Awan, Dilip Joseph and Vyas Sekar, an academic collaborator and now Professor of Carnegie Mellon University. The paper pioneered large-scale video measurements and documented an in-depth study conducted on how video quality affects user engagement, which has had a lasting impact on the optimization of streaming media.
The State of Streaming
While video streaming quality has significantly improved in the past 10 years, consumer expectations have also risen to new heights. Nothing short of high resolution and smooth playback all-the-time is acceptable. Detection and identifying root-cause of any barriers to an excellent experience is more challenging than ever due to the complexity of today’s streaming technology ecosystem. Diverse mobile-connected TV devices and associated video/app tech stacks, sophisticated cloud-based media preparation, content distribution, and advertising tech stacks all can contribute to more microscopic and subtle failure modes. More than a trillion-dollar market (ranging from media, entertainment, sports, education and fitness industries) is built on top of streaming, making it table stakes to ensure every media consumer has the best experience.
Each quarter, Conviva conducts an in-depth global review of streaming quality and adoption in a report entitled The State of Streaming.
2022 SIGCOMM Networking Systems Award
A separate SIGCOMM award committee also selected Conviva as the recipient of the 2022 SIGCOMM Networking Systems Award, recognizing the development of a networking system that has had a significant impact on the world of communications and computer networks. According to the committee, Conviva was recognized for “the sustained impact that Conviva has had, from the earliest days of translating published research to a successful real-world system, making a significant impact on real-world streaming systems and CDNs and then continuing to give back to the research community via data sharing and publications.”
“While I am very proud that Conviva has been recognized for its impact on the industry, our contribution to the research community is also very meaningful,” added Zhang. “I am thankful to all of our academic collaborators and talented undergrad and graduate interns from top research programs at CMU, Berkeley, Chicago, Purdue, and USC.”
The 2022 Test of Time winners were selected by an esteemed committee of technology experts that included Fadel Adib (MIT), Venkat Padmanabhan (Microsoft Research India, chair), Jennifer Rexford (Princeton) and Renata Teixeira (Netflix). The 2022 SIGCOMM Networking Systems Award was selected by a committee that included Vishal Misra, Anees Shaikh and Puneet Sharma.
About ACM SIGCOMM
The Association for Computing Machinery (ACM) is the world’s largest educational and scientific computing society, and SIGCOMM is ACM’s professional forum for the discussion of topics in the field of communications and computer networks, including technical design and engineering, regulation and operations, and the social implications of computer networking. The SIG's members are particularly interested in the systems engineering and architectural questions of communication.
About Conviva
Conviva helps streaming businesses act within seconds of observation to grow their business ahead of the competition. Conviva’s leading global streaming analytics platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. Using just a single sensor and a single pipeline, its 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today the Conviva platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. To learn more, visit www.conviva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005274/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
